Fibroblast Growth Factor 23 (FGF23) Antibody (HRP)

Background

FGF23 is a phosphaturic hormone primarily secreted by osteocytes and osteoblasts in bone tissue. It regulates phosphate homeostasis and vitamin D metabolism by reducing phosphate reabsorption in the kidneys and suppressing the synthesis of 1,25-dihydroxyvitamin D. FGF23 binds to its receptor in the presence of α-Klotho, promoting phosphate excretion to maintain serum phosphate levels. Elevated FGF23 levels are associated with chronic kidney disease (CKD), where impaired renal function leads to hyperphosphatemia and secondary hyperparathyroidism. Mutations in FGF23 can cause disorders like hypophosphatemic rickets and osteomalacia, characterized by bone mineralization defects. FGF23’s role in phosphate balance and bone health makes it a key target for managing CKD and related mineral metabolism disorders.